Takara Bio Inc.

Equities

4974

JP3460200003

Biotechnology & Medical Research

Market Closed - Japan Exchange 02:00:00 2024-04-23 am EDT 5-day change 1st Jan Change
1,008 JPY +1.92% Intraday chart for Takara Bio Inc. +3.81% -19.49%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index CI
Takara Bio's Attributable Income Falls 98.9% in Fiscal Nine Months MT
Takara Bio Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024 CI
Jefferies Adjusts Takara Bio’s Price Target to 1,900 Yen From 2,000 Yen, Keeps at Hold MT
Takara Bio Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023 CI
Takara Bio Inc. Revised Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 CI
Takara Bio Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 CI
Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023 CI
Takara Bio Posts Extraordinary Gains and Losses over Subsidy Grants MT
Takara Bio Inc. Revises Year End Dividend Guidance for the Full Year Ending March 31, 2022 CI
Takara Bio Inc. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2022 CI
Takara Bio : Raises Earnings Forecast for Fiscal H1 MT
Takara Bio Eligible to List on Tokyo Bourse's Prime Market MT
Takara Bio Inc. Provides Dividend Guidance for the Year Ending March 31, 2022 CI
Takara Bio Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2021 CI
Takara Bio Inc. Provides Earnings Guidance for the Six Months Ending September 30, 2021 and Full Year Ending March 31, 2022 CI
Takara Bio Inc. Reports Unaudited Consolidated Earnings Results for the Year Ended March 31, 2021 CI
Takara Bio Inc. Announces Dividend for the Year Ended March 31, 2021 CI
Takara Bio Inc. Provides Dividend Guidance for the Year Ending March 31, 2022 CI
Takara Bio Inc. Provides Earnings Guidance for the Six Months Ending September 30, 2021; Provides Earnings Guidance for the Year Ending March 31, 2022 CI
Takara Bio : Attribute Net Income Surges 111% in April-December 2020 MT
Takara Bio Inc. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2020 CI
Takara Bio Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2021 CI
Takara Bio Inc. Provides Year End Dividend Guidance for the Fiscal Year Ending March 31, 2021 CI
Chart Takara Bio Inc.
More charts
TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
989 JPY
Average target price
1,600 JPY
Spread / Average Target
+61.78%
Consensus
  1. Stock Market
  2. Equities
  3. 4974 Stock
  4. News Takara Bio Inc.
  5. Takara Bio's Attributable Income Falls 98.9% in Fiscal Nine Months